BRIEF-EC grants Abbvie's Maviret marketing authorization for treatment of Chronic Hepatitis C
July 28, 2017 at 12:49 PM EDT
* European Commission grants Abbvie's Maviret (glecaprevir/pibrentasvir) marketing authorization for the treatment of Chronic Hepatitis C in all major genotypes (GT1-6)
